相关实验视频

Updated: Jun 28, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

在COVID-19患者中,通过ACE2-交叉反应性抗SARS-CoV-2 RBD抗体增强NETosis

Kun-Han Hsieh¹, Chiao-Hsuan Chao^1,2, Yi-Ling Cheng¹

¹Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Journal of biomedical science

|April 18, 2024

概括

交叉反应性抗体 (CR Abs) 通过增强中性粒细胞外细胞陷 (NET) 形成来加剧COVID-19. ACE2和达萨提尼布显示出作为治疗的潜力,而疫苗接种减少了严重程度和CR Abs的产生.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
病理学病理学病理学

背景情况:

中性粒细胞外细胞陷 (NET) 形成和自身抗体与严重的COVID-19相关.
对抗SARS-CoV-2 RBD的人类血管素转化酶2 (ACE2) 交叉反应抗体 (CR Abs) 与抗ACE2自身抗体有关.
在COVID-19期间CR Abs在NET形成中的作用尚不清楚.

研究的目的:

为了调查CR Abs和COVID-19严重程度之间的关联.
为了确定CR Abs对NETosis的影响.
探索潜在的治疗点和疫苗接种的作用.

主要方法:

来自COVID-19患者的血清和IgG被分析为CR Abs.
评估了CR Abs和特定单克隆抗体 (mAb 127) 对NETosis的影响.
研究了涉及ACE2,Fc受体和激酶抑制剂的机制.

主要成果:

在120名患者中,CR Abs水平与COVID-19严重程度相关.
CR Abs和SARS-CoV-2 RBD触发了NETosis,激活了与血栓相关的细胞.
通过破坏CR Abs-ACE2相互作用或使用ACE2/dasatinib来阻止NETosis诱导.
接种COVID-19疫苗可以减少疾病的严重程度和CR Abs的产生.

结论:

通过增强NETosis,CR Abs可能会使COVID-19恶化.
ACE2和达沙替尼布是潜在的治疗干预措施.
接种疫苗有助于减少COVID-19的严重程度和CR Abs的产生.

关键词:

反-ACE2自身抗体的自体抗体在 COVID-19 疫情中,交叉反应性交叉反应性网症 (NETosis) 是一种疾病.血栓形成的原因之一是血栓形成.

更多相关视频

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

相关概念视频

Cross-reactivity

Cross-reactivity

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...